Skip to content
value.today
Cognition Theraputics Inc. logo

Cognition Theraputics Inc.

Total raised
$32 M
7 rounds on record
Latest round
$2 M
Nov 2018
First round on record
Dec 2010
Today
Went public
See the company page

Cognition Theraputics Inc. is listed today as Cognition Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cognition Theraputics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$2 MNo. 7Under $2 million

Cognition Theraputics Inc.: Raise no. 7, Nov 2018

Investors in this round

28 investors had bought by the notice of Nov 28, 2018: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $8 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$665,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth I. Moch · Executive Officer, Director
  • Susan I. Catalano · Executive Officer, Director
  • Aaron I. Fletcher · Director
  • Irwin I. Scher · Director
  • Mark I. Breedlove · Director
  • Peggy I. Wallace · Director
  • Robert I. Gailus · Director
  • Stephen I. Sands · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth I. Moch, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 28, 2018. Read the notice at the SEC.

debt, optionsSEC
Mar 2018$2 MNo. 6$2 to $10 million

Cognition Theraputics Inc.: Raise no. 6, Mar 2018

Investors in this round

31 investors had bought by the notice of Mar 15, 2018: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
$1,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$575,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth I. Moch · Executive Officer, Director
  • Susan I. Catalano · Executive Officer, Director
  • Aaron I. Fletcher · Director
  • Irwin I. Scher · Director
  • Mark I. Breedlove · Director
  • Peggy I. Wallace · Director
  • Robert I. Gailus · Director
  • Stephen I. Sands · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth I. Moch, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 15, 2018. Read the notice at the SEC.

debt, optionsSEC
Nov 2016$4 MNo. 5$2 to $10 million

Cognition Theraputics Inc.: Raise no. 5, Nov 2016

Investors in this round

50 investors had bought by the notice of Jan 18, 2017: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $7 M offered; $2 M still to sell
Smallest investment taken
$1,340
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$937,500 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Moch · Executive Officer, Director
  • Susan Catalano · Executive Officer, Director
  • Aaron Fletcher · Director
  • Irwin Scher · Director
  • Mark Breedlove · Director
  • Peggy Wallace · Director
  • Robert Gailus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth I. Moch, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 18, 2017. Read the notice at the SEC.

equitySEC
Mar 2016$3 MNo. 4$2 to $10 million

Cognition Theraputics Inc.: Raise no. 4, Mar 2016

Investors in this round

41 investors had bought by the notice of Mar 31, 2016: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $1 M still to sell
Smallest investment taken
$647
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$280,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harold Safferstein · Executive Officer, Director
  • Susan Catalano · Executive Officer, Director
  • Aaron Fletcher · Director
  • Franz Hefti · Director
  • Irwin Scher · Director
  • Mark Breedlove · Director
  • Nada Jain · Director
  • Robert Gailus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harold T. Safferstein, President and CEO. Source: SEC Form D, newest notice filed Mar 31, 2016. Read the notice at the SEC.

debt, optionsSEC
Mar 2014$16 MNo. 3$10 to $50 million

Cognition Theraputics Inc.: Raise no. 3, Mar 2014

Investors in this round

56 investors had bought by the notice of Jul 22, 2015: 56 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $17 M offered; $1 M still to sell
Smallest investment taken
$3,000
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$305,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harold Safferstein · Executive Officer, Director
  • Susan Catalano · Executive Officer, Director
  • Franz Hefti · Director
  • Mark Breedlove · Director
  • Nada Jain · Director
  • Robert Gailus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes cash proceeds and proceeds of indebtedness of the Issuer converted in the offering.”

Signed by Harold T. Safferstein, President and Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Jul 22, 2015. Read the notice at the SEC.

equitySEC
Dec 2011$2 MNo. 2Under $2 million

Cognition Theraputics Inc.: Raise no. 2, Dec 2011

Investors in this round

16 investors had bought by the notice of Dec 6, 2011: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harold T. Safferstein · Executive Officer, Director
  • Susan Catalano · Executive Officer, Director
  • Franz T. Hefti · Director
  • Mark T. Breedlove · Director
  • Nada T. Jain · Director
  • Robert T. Gailus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harold T. Safferstein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 6, 2011. Read the notice at the SEC.

equitySEC
Dec 2010$3 MNo. 1$2 to $10 million

Cognition Theraputics Inc.: Raise no. 1, Dec 2010

Investors in this round

22 investors had bought by the notice of Dec 28, 2010: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Cognition Theraputics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harold T. Safferstein · Executive Officer, Director
  • Susan Catalano · Executive Officer, Director
  • Franz F. Hefti · Director
  • Mark F. Breedlove · Director
  • Nada F. Jain · Director
  • Robert T. Gailus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harold T. Safferstein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 28, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cognition Theraputics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).

    SEC Form D · Nov 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2018

That is all the official record says: Cognition Theraputics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cognition Theraputics Inc. are on record.

Investors#

19 named in official filings. Open an investor to see everything it has backed.

Investors in Cognition Theraputics Inc.
InvestorKindAmountRoundRoleSource
BIOS Advisors GP, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Capital Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Equity Partners III, LPPrivate equitynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Bios Equity Partners II, LPPrivate equitynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Bios Equity Partners, LPPrivate equitynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund III, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund III NT, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund III QP, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund II, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund II NT, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund II QP, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund I, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Fund I QP, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Memory SPV II, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
BIOS Memory SPV I, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Cavu Advisors, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Cavu Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Golden Seeds Cognition Therapeutics LLCVenture capitalnot statednot statedHeld Series A-1, A-2, B and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Ogden CAP Associates, LLCOthernot statednot statedHeld Series A, A-1, A-2, B and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 56 investors.

Largest shareholders today

Institutions holding Cognition Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cognition Theraputics Inc.
NameRoleNamed in
Kenneth I. MochExecutive officerNov 2018
Susan I. CatalanoExecutive officerNov 2018
Kenneth MochExecutive officerJan 2017
Susan CatalanoExecutive officerJan 2017
Harold SaffersteinExecutive officerMar 2016
Harold T. SaffersteinExecutive officerDec 2011
Aaron I. FletcherDirectorNov 2018
Irwin I. ScherDirectorNov 2018
Kenneth I. MochDirectorNov 2018
Mark I. BreedloveDirectorNov 2018
Peggy I. WallaceDirectorNov 2018
Robert I. GailusDirectorNov 2018
Stephen I. SandsDirectorNov 2018
Susan I. CatalanoDirectorNov 2018
Aaron FletcherDirectorJan 2017
Irwin ScherDirectorJan 2017
Kenneth MochDirectorJan 2017
Mark BreedloveDirectorJan 2017
Peggy WallaceDirectorJan 2017
Robert GailusDirectorJan 2017
Susan CatalanoDirectorJan 2017
Franz HeftiDirectorNov 2016
Harold SaffersteinDirectorMar 2016
Nada JainDirectorMar 2016
Franz T. HeftiDirectorDec 2011
Harold T. SaffersteinDirectorDec 2011
Mark T. BreedloveDirectorDec 2011
Nada T. JainDirectorDec 2011
Robert T. GailusDirectorDec 2011
Franz F. HeftiDirectorDec 2010
Mark F. BreedloveDirectorDec 2010
Nada F. JainDirectorDec 2010

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.